Ohio State Navbar

Directory

Amy Johnson, PhD


Staff photo

410 W 12th Ave
OSU CCC Bldg. Room 455C
Columbus, OH 43210

Phone: (614) 685-2341

Email: johnson.2349@osu.edu

 

Current OSU Appointments

Associate Professor, Hematology

Associate Professor, Pharm CBO/Coll

 

Clinical Interest

Chronic Lymphocytic Leukemia - CLL

Advising Narrative

I have been involved in the summer mentoring of students for our Hendrix College-The Ohio State University CLL Experimental Therapeutics Laboratory Summer Internship Program.

Noteworthy Graduate Narrative

I am a P status advisor for College of Pharmacy, Division of Pharmaceutics and the College of Medicine, Biomedical Sciences Graduate Program, (formerly IBGP). Sarah May Herman was an IBGP student who graduated with three first-author papers in Blood and went on to do a post-doctoral fellowship at the NIH. Dolly Rozewski was a Pharmaceutics PhD student and graduated with a first-author paper and is finishing her projects with Mitch Phelps in the College of Pharmacy as a post-doctoral fellow. Current PhD student, Ta-Ming Liu was awarded a Pelotonia fellowship in 2012.

Postdoctoral / Researcher Advising

I have mentored both PhD and MD post-doctoral researchers. Jennifer Woyach, MD was a hematology-oncology medical fellow that trained in my group studying BTK inhibitors in our mouse models. She is now a tenure-track faculty within the Division of Hematology, OSU and is the phase III clinical trial through the Alliance for Clinical Trials in Oncology cooperative group study chair. Her work has led to a Leukemia and Lymphoma Society Fellow award and a favorably scored K23 award. Kami Maddocks, MD was another hematology-oncology medical fellow that trained in my group who is now a tenure-track faculty in our Division and received a National Comprehensive Cancer Network (NCCN) award for a clinical trial with ibrutinib comparing outcomes in high and low-risk genetics CLL patients.

Academic Advising

2016 Sara El-Gamal, The Ohio State University. Graduated 0.
2010 - 2011 Kami Maddocks, The Ohio State University. Graduated 2005.
2011 Leif Jacobson, The Ohio State University. Graduated 2011.
2009 - 2012 Darlene Rozewski, The Ohio State University. Graduated 2012.
2011 - 2012 Jennifer Woyach, The Ohio State University. Graduated 2005.
2009 - 2013 Emilia Mahoney, The Ohio State University. Graduated 2009.
2013 C-H Wang, The Ohio State University. Graduated 2013.
2011 - 2015 Yuh-Ying Yeh, The Ohio State University. Graduated 2010.
 

Conferences

Induction of Apoptosis by Cyclooxygenase-2 Inhibitors in Prostate Cancer Cells

Aberrant DNA methylation in chronic lymphocytic leukemia: A role in pathogenesis?

Is cyclooxygenase-2 a player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells?

Hu1D10 induces parallel death and survival signals in chronic lymphocytic leukemia (CLL) cells: Justification for combination studies of Hu1D10 with PI3 kinase inhibitors.

Rituximab and 17-AAG synergistically induce apoptosis in B-cell chronic lymphocytic leukemia (CCL)

Hu1D10 activates both death and survival pathways in primary human chronic lymphocytic leukemia cells: Hu1D10 induced reactive oxygen species activate the AKT survival pathway.

Rituximab and 17-AAG synergistically induce apoptosis in B-cell chronic lymphocytic leukemia (CLL).

Flavopiridol given as a 30-min intravenous (IV) bolus followed by 4-hr continuous IV infusion (CIVI) results in clinical activity and tumor lysis in refractory chronic lymphocytic leukemia (CLL).

A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma via a caspase and Bcl-2 independent mechanism.

The TCL-1 transgenic mouse is an effective tool for pre-clinical drug development in chronic lymphocytic leukemia

The TCL-1 transgenic mouse is an effective tool for pre-clinical drug development in chronic lymphocytic leukemia

The novel histone deacetylase inhibitor OSU-HDAC42 has class I and II histone deacetylase (HDAC) inhibitory activity and represents a novel therapy for chronic lymphocytic leukemia.

Flavopiridol decreases Mcl-1 and initiates early mitochondrial damage in chronic lymphocytic leukemia (CLL) cells.

Silvestrol, a rocaglate derivative from the Indonesian plant Aglaia foveolafa, has significant Bcl-2-and p53-independent anti-tumor activity against chronic lymphocytic leukemia cells.

The geldanalmycin derivative DMAG demonstrates improved cytotoxicity and down-modulation of Hsp90 client proteins relative to 17-AAG in chronic lymphocytic leukemia (CLL) cells: Justification for clinical trials in CLL.

OSU03012, a novel celecoxib derivative, induces apoptogis in multiple myeloma cells independently of caspase activation.

Phase I study of a novel, pharmacokinetically derived schedule of flavopiridol in acute leukemias: Clinical efficacy including hyperacute tumor lysis, pharmacokinetics, and pharmacodynamics.

Updated results of a phase I study of flavopiridol in acute leukemias using a novel, pharmacolkinetically derived schedule: Clinical activity including hyperacute tumor lysis syndrome (TLS), pharmacokinetics (PIC), and pharmacodynamics (PD).

Preliminary results of a phase II study of flavopiridol (Alvocidib) in, relapsed chronic lymphocytic leukemia (CLL): Confirmation of clinical activity in high-risk patients and achievement of complete responses (CR).

Early fludarabine treatment of TCL-1 transgenic mice promotes drug resistance through a mechanism not involving p53 mutations: Implications for patients with chronic lymphocytic leukemia (CLL).

Unacceptable toxicity of lenalidomide when administered to CLL patients at higher doses

Clinical activity of flavopiridol in relapsed and refractory chronic lymphocytic leukemia (CLL) with high-risk cytogenetic abnormalities: Updated data on 89 patients (Pts).

The plant-derived agent silvestrol has B-Cell selective activity in vitro in chronic lymphocytic leukemia patient cells and in vivo in the Tcl-1 mouse model of CLL

Final results of a dose escalation study of flavopiridol in acute leukemias using a novel-treatment schedule

Loss of Id4 Accelerates CLL Progression in TCL1 Mice

Preliminary results of a phase I trial with dose escalated lenalidomide (L) in separate cohorts of relapsed acute leukemia (AL) or chronic lymphocytic leukemia (CLL): evidence of activity in acute myeloid leukemia (AML) and toxicity in CLL at starting dose

Flavopiridol (Alvocidib) Induces Durable Responses in Relapsed Chronic Lymphocytic Leukemia (CLL) Patients with High-Risk Cytogenetic Abnormalities

Epigenetic Contributions to Chronic Lymphocyte Leukemia

17-DMAG Targets the NF-kappa B Family of Proteins to Induce Apoptosis in CLL: Clinical Implications of Hsp90 Inhibition

CAL-101, a Potent Selective Inhibitor of the p110d Isoform of Phosphatidylinositol 3-Kinase, Attenuates PI3K Signaling and Inhibits Proliferation and Survival of Acute Lympoblastic Leukemia in Addition to a Range of Other Hematological Malignancies

CAL-101, a Selective Inhibitor of the p110 delta Isoform of Phosphatidylinositol 3-Kinase, Effectively Induces Apoptosis in Primary Chronic Lymphocytic Leukemia Cells Providing a Novel Therapeutic Strategy for the Treatment of This Disease

Chronic lymphocytic leukemia (CLL) patients with high-risk cytogenetics respond to treatment with flavopiridol: Study of 120 patients (pts) with relapsed, genetically high risk CLL

Preliminary Results of a Phase I Study of Lenalidomide in Relapsed Chronic Lymphocytic Leukemia.

CAL-101, An Oral p110 delta Selective Phosphatidylinositol-3-Kinase (PI3K) Inhibitor for the Treatment of B Cell Malignancies Inhibits PI3K Signaling, Cellular Viability and Protective Signals of the Microenvironment

The HSP90 Inhibitor 17-DMAG Targets NF-kappa B to Induce Apoptosis in CLL and Prolongs Survival in a CLL Mouse Model

The Cyclin Dependent Kinase Inhibitor SCH 727965 Demonstrates Promising Pre-Clinical and Early Clinical Activity in Chronic Lymphocytic Leukemia

Lenalidomide-Dependent Activation of the Phosphatidylinositol 3-kinase-delta Pathway Is Antagonized by CAL-101 In Chronic Lymphocytic Leukemia.

Autophagy Is a Relevant Cellular Process In CLL and Contributes to Drug Resistance of Flavopiridol

Flavopiridol Treatment of Patients Aged 70 or Older with Refractory or Relapsed Chronic Lymphocytic Leukemia Is Feasible and Not Associated with Adverse Outcome When Compared to Younger Patients

Phase 1 Trial of Flavopiridol and Lenalidomide In Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL)

Risk Factors for Tumor Lysis Syndrome (TLS) In Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Cyclin Dependent Kinase Inhibitor, Flavopiridol

Micro-RNA and Gene Expression In CLL: Network Analysis Elucidating the Complex Role of the NF-kappa B Signaling Pathway In Disease

Phase I Trial of Flavopiridol In Relapsed Myeloma: Brief Response In t(4;14) with Significant Neutropenia

Flavopiridol Can Be Safely Administered Using a Pharmacologically Derived Schedule and Demonstrates Activity In Relapsed and Refractory Non-Hodgkin's Lymphoma

Response, Progression-Free Survival, and Overall Survival of patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Flavopiridol: Impact of Poor Risk Cytogenetic Abnormalities

Dinaciclib (SCH727965) Is a Novel Cyclin Dependent Kinase Inhibitor That Promotes Selective Apoptosis In CLL Cells and Abrogates the Protective Effects of Microenvironment Cytokines

Update on the Phase I Study of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH 727965) In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity and Feasibility of Long-Term Administration.

The Kinase Inhibitor, PCI-32765, Demonstrates Activity In Chronic Lymphocytic Leukemia Cells Independent of Microenvironmental Survival Signals

The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study

The contribution of P-glycoprotein to clinical pharmacokinetic interactions between lenalidomide and temsirolimus

Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals

THE BTK INHIBITOR PCI-32765 IS HIGHLY ACTIVE AND TOLERABLE IN PATIENTS WITH POOR-RISK CLL: INTERIM RESULTS FROM A PHASE IB/II STUDY

Activity of Combined Flavopiridol and Lenalidomide in Patients with Cytogenetically High Risk Chronic Lymphocytic Leukemia (CLL): Updated Results of a Phase I Trial.

A Novel Approach for Charaterization Histone Isoform Distrubution Across Cellular Coparments

Activity and tolerability of he Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 in patients with chronis lymphocytic leukemia/small lymphocytic lymphoms (CLL/SLL): Interim results of a phase Ib/II stdy

Treatment with Auranofin Induces Oxidative and Lethal Endoplasmic Reticulum (ER) Stress Exerting Single Agent Activity Against Primary CLL Cells

Phase I study of the CDK inhibitor dinaciclib (SCH 727965) in patients (pts) with relapsed/refractory CLL

The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 (P) in treatment-naive (TN) chronic lymphocytic leukemia (CLL) patients (pts): Interim results of a phase Ib/II study.

The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naive (TN) and Relapsed or Refractory (RR) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Patients Including Patients with High-Risk (HR) Disease: New and Updated Results of 116 Patients in a Phase Ib/II Study

Global Inhibition of Bruton's Tyrosine Kinase (BTK) Delays the Development and Expansion of Chronic Lymphocytic Leukemia (CLL) in the TCL1 Mouse Model of Disease

A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases

Identification of Endoplasmic Reticulum Stress Inducing Agents by Antagonizing Autophagy: A New Potential Strategy for Identification of Anti-Cancer Therapeutics in B-Cell Malignancies

Ibrutinib Is an Irreversible Molecular Inhibitor of Interleukin-2 Inducible Kinase: Expanding Therapeutic Potential and Modulating a Th1 Selective Pressure in CD4 T-Cells

A Phase I Trial of the Intravenous (IV) Hsp90 Inhibitor 17-DMAG (alvespimycin) in Patients (pts) with Relapsed Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

The Hsp90 Inhibitor 17-DMAG Increases SOCS3 and Regulates Cytokine Production, Migration and Cell Death in Chronic Lymphocytic Leukemia

Changing The Treatment Paradigm For Previously Treated Chronic Lymphocytic Leukemia Patients With Del(17p) Karyotype

Use of tumor genomic profiling to reveal mechanisms of resistance to the BTK inhibitor ibrutinib in chronic lymphocytic leukemia (CLL).

Ibrutinib (PCI-32765) administration modulates a Th1 dominated immune response during cutaneous leishmaniasis infection

Immune modulating agent ibrutinib blocks T-helper 17 activation and release of IL-17A while preserving T-regulatory cell function

ACP-196: A second generation Btk inhibitor demonstrates biologic activity in a canine model of B-cell non-Hodgkin lymphoma

Ibrutinib can reverse established chronic graft-versus-host disease, which is dependent upon IL-2 inducible T-cell kinase (ITK) and Bruton's tyrosine kinase (BTK)-driven lymphocyte activation

DINACICLIB AND DINACICLIB GLUCURONIDE PHARMACOKINETICS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA.

Association of disease progression on ibrutinib therapy with the acquisition of resistance mutations: A single-center experience of 267 patients.

A PHASE 2 STUDY OF THE BTK INHIBITOR IBRUTINIB IN GENETIC RISK-STRATIFIED RELAPSED AND REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL)

A phase 1b/2 study evaluating activity and tolerability of the BTK inhibitor ibrutinib in combination with ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases.

Covariation of psychological and inflammatory variables in patients with chronic lymphocytic leukemia receiving ibrutinib.

Bcl-xL dependence predicts response to alvocidib in chronic lymphocytic leukemia patients

Pharmacologic Inhibition with Duvelisib (IPI-145) and Genetic Inhibition of PI3K p110 delta Antagonizes Intrinsic and Extrinsic Survival Signals in Chronic Lymphocytic Leukemia (CLL)

DISEASE PROGRESSION ON IBRUTINIB THERAPY IS UNCOMMON AND IS ASSOCIATED WITH THE ACQUISITION OF RESISTANCE MUTATIONS: A SINGLE CENTER EXPERIENCE OF 267 PATIENTS

Covariation of psychological and inflammatory variables in patients with chronic lymphocytic leukemia receiving ibrutinib.

Mir-155 Expression Is Associated with Chemoimmunotherapy Outcome and Is Modulated By Bruton's Tyrosine Kinase Inhibition with Ibrutinib

A Dose Escalation Study of Ibrutinib with Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Dinaciclib (SCH 727965) and Ofatumumab for the Treatment of Relapsed and Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): Results of a Phase 1b/2 Study

Distinct biomarkers as prognostic in chronic lymphocytic leukemia patients treated with alvocidib and lenalidomide as single agents or combination regimens thereof.

Independent evaluation of ibrutinib efficacy 3 years post-initiation of monotherapy in patients with chronic lymphocytic leukemia/small lymphocytic leukemia including deletion 17p disease.

Synergistic activity of lenalidomide and interleukin-21 in chronic lymphocytic leukemia

Targeting BTK By a microRNA Mechanism in Chronic Lymphocytic Leukemia

PHARMACOKINETICS/PHARMACODYNAMICS/PHARMACOGENETICS OF DINACICLIB AND DINACICLIB GLUCURONIDE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

Activity and Tolerability of Ibrutinib in Combination With Ofatumumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

The Bruton Tyrosine Kinase (BTK) Inhibitor ACP-196 Demonstrates Clinical Activity in Two Mouse Models of Chronic Lymphocytic Leukemia

Pharmacologic inhibition with IPI-145 and genetic inhibition of PI3K p110 delta antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia

NFkB p50 (Nfkb1) Contributes to Disease in the Eu-TCL1 Mouse Model of Chronic Lymphocytic Leukemia

ACP-196 Is a Second Generation Inhibitor of Bruton Tyrosine Kinase (BTK) with Enhanced Target Specificity

Ibrutinib Treatment Reduces Both T-Regulatory Cells and B-Regulatory Cell Phenotype in Malignant B Cells in Chronic Lymphocytic Leukemia Patients

The E mu-Myc/TCL1 Transgenic Mouse As a New Aggressive B-Cell Malignancy Model Suitable for Preclinical Therapeutics Testing

Genetic Inhibition of PI3K p110delta Antagonizes Survival Signals and Induces Immune Activation in Chronic Lymphocytic Leukemia (CLL)

Long-Term Efficacy and Safety of Single-Agent Ibrutinib at 3 Years Follow-up in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL)

 

Degrees

1997 B.A., DePauw University

2002 Ph.D., University of Kentucky

 

Editorial Activities

2008 - present Blood
2008 - present Leukemia and Lymphoma
2009 American Society of Hematology Annual Meeting Abstract Reviewer, Molecular Pharmacology
2010 - present Blood Cells, Molecules and Diseases
2010 American Society of Hematology Annual Meeting, Molecular Pharmacology. Committee Chair
2011 - present Expert Opinion on Investigational Drugs
2011 American Society of Hematology Annual Meeting Abstract Reviewer, Molecular Pharmacology
2012 American Society of Hematology Annual Meeting Abstract Reviewer, CLL Biology
2013 - present Pharmaceutical Research
2015 Improving therapeutic activity of anti-CD20 mAbtherapy through immunomodulation in lymphoid malignancies
 

Honors

1995 Howard Hughes Foundation Summer Fellowship. Howard Hughes Medical Institute.
1996 ASPET Research Fellowship. American Society for Pharmacology and Experimental Therapeutics.
2000 ASPET Graduate Student Travel Award. American Society for Pharmacology and Experimental Therapeutics.
2002 ASPET Student Travel Award. American Society for Pharmacology and Experimental Therapeutics.
2003 - 2006 IDEC/Genetech/Ronald Levy Postdoctoral Fellowship. American Cancer Society.
 

Journal Articles

"Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. Vol. 106, no. 32. (August 2009.): -.

.

 

Reference Works

January 2002 Johnson AJ, Hsu AL, Song X, Ching TT, Chen CS."Induction of Apoptosis by Cyclooxygenase-2 Inhibitors in Prostate Cancer Cells." .
January 2002 Johnson AJ, Song X, Lin HP, Chen CS."Is Cyclooxygenase-2 a Player or Spectator in Cyclooxygenase-2 Inhibitor-Induced Apoptosis in Prostate Cancer Cells" .
January 2002 Mone AP, Lucas D, Aron J, Cheney C, Johnson AJ, Bains SK, Tso JY, Weiner G, Green J, Grever M, Byrd JC."Hu1D10 Induces Parallel Death and Survival Signals in Chronic Lymphocytic Leukemia (CLL) Cells: Justification for Combination Studies of Hu1D10 with PI3 Kinase Inhibitors" .
January 2003 Johnson AJ, Eisenbeis CF, Cheney CM, Mone AP, Lucas DM, Byrd JC."Rituximab and 17-AAG Synergistically Induce Apoptosis in B-Cell Chronic Lymphocytic Leukemia (CLL)" .
January 2004 Johnson AJ, Smith L, Zhu J, Heerema N, Guster S, Mone A, Grever M, Chen CS, Byrd JC."A Novel Celecoxib Derivative, OSU03012, Induces Cytotoxicity in Primary CLL Cells and Transformed B-Cell Lymphoma Via a Caspase and Bcl-2 Independent Mechanism" .
January 2006 Lucas DM, Hussain SA, Johnson AJ, Smith LL, Wagner AJ, Allison JM, Guster SE, Lin TS, Byrd JC, Julian MW, Crouser ED, Grever MR."Flavopiridol Decreases Mcl-1 and Initiates Early Mitochondrial Damage in Chronic Lymphocytic Leukemia (CLL) Cells" .
January 2006 West DA, Lucas DM, Davis ME, De Lay MD, Johnson AJ, Guster SE, Freitas MA, Parthun MR, Wang D, Kulp SK, Grever MR, Chen C-S, and Byrd JC."The Novel Histone Deacetylase Inhibitor OSU-HDAC42 Has Class I and II Histone Deacetylase (HDAC) Inhibitory Activity and Represents a Novel Therapy for Chronic Lymphocytic Leukemia" .
January 2006 Blum W, Klisovic RB, Kefauver C, Johnson AJ, Phelps M, Dalton JT, Lucas DM, Huynh L, Liu S, Grever MR, Colevas AD, Marcucci G, and Byrd JC."Updated Results of a Phase I Study of Flavopiridol in Acute Leukemias Using a Novel, Pharmacokinetically Derived Schedule: Clinical Activity Including Hyperacute Tumor Lysis Syndrome (TLS), Pharmacokinetics (PK), and Pharmacodynamics (PD" .
January 2006 Edwards RB, Lucas DM, Lozanski G, Johnson AJ, Su B, Lin TS, Byrd JC, Kinghorn AD, Grever MR."“Silvestrol, a Rocaglate Derivative from the Indonesian Plant Aglaia foveolata, Has Significant Bcl-2- and p53-Independent Anti-Tumor Activity against Chronic Lymphocytic Leukemia Cells" .
January 2007 Andritsos LA, Johnson AJ, Blum W, Kefauver C, Awan F, Smith LL, Lapalombella R, Wang D-S, Knight RD, Chen C-S and Byrd JC."Unacceptable Toxicity of Lenalidomide When Administered to CLL Patients at Higher Doses" .
January 2007 Lin TS, Fischer B, Blum KA, Andritsos LA, Jones JA, Moran ME, Broering S, Heerema NA, Lozanski G, Schaaf LJ, Mahoney LS, Johnson AJ, Smith LL, Wagner AJ, Raymond CA, Phelps M, Dalton JT, Grever MR and Byrd JC."Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses (CR)" .
January 2007 Lucas DM, Edwards RB, De Lay MD, West DA, Lozanski G, Johnson AJ, Salim AA, Lin TS, Byrd JC, Kinghorn AD and Grever MR."The Plant-Derived Agent Silvestrol Has B-Cell Selective Activity In Vitro in Chronic Lymphocytic Leukemia Patient Cells and In Vivo in the Tcl-1 Mouse Model of CLL" .
January 2007 De Lay MD, Johnson AJ, Lucas DM, Durr DT, Sass EM, Goettl VM, Lehman A, Jarjoura D, Grever MR and Byrd JC,."Early Fludarabine Treatment of TCL-1 Transgenic Mice Promotes Drug Resistance through a Mechanism Not Involving p53 Mutations: Implications for Patients with Chronic Lymphocytic Leukemia (CLL)" .
January 2007 Heerema NA, Byrd JC, Andritsos LA, Lozanski G, Blum K, Fischer B, Jones JA, Moran ME, Groering S, Schaaf LJ, Mahoney LS, Johnson AJ, Smith LL, Wagner AJ, Raymond CA, Phelps MA, Dalton JT, Grever MR and Lin TS."Clinical Activity of Flavopiridol in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) with High-Risk Cytogenetic Abnormalities: Updated Data on 89 Patients" .
January 2008 Chen S-S, Johnson AJ, Claus R, Sablitzky F, Plass C, Byrd JC."Loss of Id4 Accelerates CLL Progression in TCL1 Mice" .
January 2008 Wagner AJ, Hertlein EK, Raymond CA, West DA, Flynn JM, Lin T, Johnson AJ, Byrd JC."17-DMAG Targets the NF-{kappa}B Family of Proteins to Induce Apoptosis in CLL: Clinical Implications of Hsp90 Inhibition" .
January 2008 Lannutti BJ, Meadows SA, Kashishian A, Steiner B, May S, Johnson AJ, Ulrich RG, Yu A, Gallatin MW, Byrd JC, Puri KD, Giese NA."CAL-101, a Potent Selective Inhibitor of the p110d Isoform of Phosphatidylinositol 3-Kinase, Attenuates PI3K Signaling and Inhibits Proliferation and Survival of Acute Lympoblastic Leukemia in Addition to a Range of Other Hematological Malignancies" .
January 2008 Lin TS, Heerema NA, Lozanski G, Fischer B, Blum KA, Andritsos LA, Jones JA, Flynn JM, Moran ME, Mitchell S, Johnson AJ, Phelps MA, Grever MR, Byrd JC."Flavopiridol (Alvocidib) Induces Durable Responses in Relapsed Chronic Lymphocytic Leukemia (CLL) Patients with High-Risk Cytogenetic Abnormalities" .
January 2008 May SE, Kashishian A, Lin TS, Jones JA, Flynn JM, Ulrich RG, Chen H, Yu AS, Puri KD, Lannutti BJ, Giese NA, Byrd JC, Johnson AJ."CAL-101, a Selective Inhibitor of the p110{delta} Isoform of Phosphatidylinositol 3-Kinase, Effectively Induces Apoptosis in Primary Chronic Lymphocytic Leukemia Cells Providing a Novel Therapeutic Strategy for the Treatment of This Disease" .
December 2009 Lannutti BJ, Meadows SA, Kashishian A, Steiner B, Pogosov G, Sala-Torra O, Johnson AJ,Byrd JC, Radich J, and Giese NA.."CAL-101, An Oral p110 Selective Phosphatidylinositol-3-Kinase (PI3K) Inhibitor for the Treatment of B Cell Malignancies Inhibits PI3K Signaling, Cellular Viability and Protective Signals of the Microenvironment" . : 286
December 2009 Hertlein EK, Lin TS, Wagner JA , William, II TH, Goettl VM, Zhang X, Jarjoura D, Raymond CA, West DA, Byrd JC, and Johnson AJ."The HSP90 Inhibitor 17-DMAG Targets NF-B to Induce Apoptosis in CLL and Prolongs Survival in a CLL Mouse Model" . : 732
December 2009 Maddocks K, Lapalombella R, Blum KA, Blum W, Fischer BB, Muthusamy N, Moran ME, Holtzapfel D, Byrd JC, Johnson AJ, and Andritsos L.."Preliminary Results of a Phase I Study of Lenalidomide in Relapsed Chronic Lymphocytic Leukemia." . : 3446
December 2009 Flynn JM, Johnson AJ, Andritsos L, Blum KA, Jones JA, Wiley EA, Hu W, Hessler J, Smith LL, Lucas DM, Small K, Statkevich P, Grever MR, Bannerji R, and Byrd JC.."The Cyclin Dependent Kinase Inhibitor SCH 727965 Demonstrates Promising Pre-Clinical and Early Clinical Activity in Chronic Lymphocytic Leukemia" . : 886
December 2010 Blum KA, Ruppert AS, Woyach JA, Jones JA, Andritsos L, Flynn JM, Brown B, Villalona-Calero M, Ji J, Phelps M, Johnson, AJ, Grever MR, Byrd JC."Risk Factors for Tumor Lysis Syndrome (TLS) In Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Cyclin Dependent Kinase Inhibitor, Flavopiridol" . : 1386
December 2010 Jones JA, Andritsos L, Baiocchi RA, Benson Jr. DM, Blum KA, Christian B, DeamD, Flynn JM, Johnson, AJ, Phelps M, Porcu Pierluigi, Byrd JC, Grever MR."Flavopiridol Can Be Safely Administered Using a Pharmacologically Derived Schedule and Demonstrates Activity In Relapsed and Refractory Non-Hodgkin's Lymphoma" . : 2834
December 2010 Hofmeister CC, Bowers MA, Lee S, Phelps M, Benson Jr. DM, Kraut EH, Hicks WJ, Deam D, Johnson, AJ, Farag S, Jones JA, Byrd JC."Phase I Trial of Flavopiridol In Relapsed Myeloma: Brief Response In t(4;14) with Significant Neutropenia" . : 1933
December 2010 Hertlein EK, Yu L, Zhang J, Johnson, AJ, Lucas DM, Marcucci G, Jarjoura D, Byrd JC."Micro-RNA and Gene Expression In CLL: Network Analysis Elucidating the Complex Role of the NF-B Signaling Pathway In Disease." . : 3642
December 2010 Blum KA, Jones JA, Andritsos L, Flynn JM, Deam D, Heerema NA, Phelps M, Johnson, AJ, Grever MR, Byrd JC.."Phase 1 Trial of Flavopiridol and Lenalidomide In Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL)" . : 2472
December 2010 Herman SEM, Lapalombella R, Jones JA, Andritsos L, Gordon AL, Ramanuni A, Lnnutti B, Muthusamy N, Byrd JC, Johnson, AJ."Lenalidomide-Dependent Activation of the Phosphatidylinositol 3-kinase- Pathway Is Antagonized by CAL-101 In Chronic Lymphocytic Leukemia" . : 1821
December 2010 Mahoney, E,Johnson, AJ, Wagner, AJ, Hessler, J, Gupta SV, Herman SEM, Andritsos, Jones JA, Flynn JM, Lucas DM, Grever MR, Byrd JC.."Autophagy Is a Relevant Cellular Process In CLL and Contributes to Drug Resistance of Flavopiridol" . : 691
December 2010 Stephens DM, Ruppert AS, Blum KA, Jones JA, Flynn JM, Johnson, AJ, Ji J, Phelps M, Grever MR, Byrd JC."Flavopiridol Treatment of Patients Aged 70 or Older with Refractory or Relapsed Chronic Lymphocytic Leukemia Is Feasible and Not Associated with Adverse Outcome When Compared to Younger Patients" . : 1378
December 2010 Woyach JA, Ruppert AS, Blum KA, Jones JA, Flynn JM, Johnson, AJ, Grever MR, Byrd JC, Heerema NA.."Response, Progression-Free Survival, and Overall Survival of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Flavopiridol: Impact of Poor Risk Cytogenetic Abnormalities" . : 2456
December 2010 Johnson, AJ, Smith LL, Wagner AJ, Hessler J, Flynn JM, Jones JA, Zhang X, Lehman A, Jarjoura D, Grever MR, Bannerji R, Byrd JC."Dinaciclib (SCH727965) Is a Novel Cyclin Dependent Kinase Inhibitor That Promotes Selective Apoptosis In CLL Cells and Abrogates the Protective Effects of Microenvironment Cytokines" . : 971
December 2010 Herman SEM, Gordon AL, Mahoney E, Jaglowski SM, Blum KA, Buggy J, Hamdy A. Byrd JC, Johnson, AJ."The Kinase Inhibitor, PCI-32765, Demonstrates Activity In Chronic Lymphocytic Leukemia Cells Independent of Microenvironmental Survival Signals" . : 1385
December 2010 Flynn JM, Jones JA, Andritsos L, Blum KA, Johnson, AJ, Hessler J, Wiley E, Poon J, Small K, Statkevich P, Grever MR, Bannerji R, Byrd JC."Update on the Phase I Study of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH 727965) In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity and Feasibility of Long-Term Administration" . : 2834
December 2011 Lapalombella R, Ramanunni A, Yeh Y-Y, Wang L, Jha S, Staubli J, Herman SEM, Andritsos LA, Jones JA, Flynn JM, Mo X, Johnson, AJ, Thompson P, Algate PA, Stromatt S, Freitas MA, Muthusamy N, Byrd JC."Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Siggnals" .
December 2011 O'Brien S, Burger JA, Blum KA, Furman RR, Coutre SE, Sharman J, Flinn IW, Grant B, Heerema NA, Johnson, AJ, Navarro T, Holmgren E, Hedrick E, Byrd JC."The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study" .
June 2011 Flynn JM, Jones JA, Andritsos L, Blum KA,Johnson AJ, Hessler J, Wiley E, Heerema NA, Poon J, Small KA, Y. Jou, Zhang D, Statkevich P, Grever MR, Bannerji R, Byrd JC."Phase I study of the CDK inhibitor dinaciclib (SCH 727965) in patients (pts) with relapsed/refractory CLL." .
July 2011 Yang X, Hofmeister CC, Rozewski DM, Lee S, Chen P, Johnson AJ, Liu Z, Hade EM, Ji J, Schaaf LJ, Benson DM, Kraut EH, Hicks WJ, Chan KK, Chen C-S, Farag SS, Grever MR, Byrd JC, Phelps MA.."The contribution of P-glycoprotein to clinical pharmacokinetic interactions between lenalidomide and temsirolimus" . : 5473
December 2011 Rao R, Maddocks K, Johnson, AJ, Chauhan L, Kambhampati S, Ganguly S, Reyes R, Aljitawi OS, Schorno K, Ford K, Dickman E, Byrd JC, Bhall KN."Treatment with Auranofin Induces Oxidative and Lethal Endoplasmic Reticulum (ER) Stress Exerting Single Agent Activity Against Primary CLL Cells" .
June 2011 Harshman, SE, Johnson, AJ, Byrd, JC, Freitas, MA."A Novel Approach for Characterization Histone Isoform Distribution Across Cellular Copartments" .
December 2011 Blum KA, Wei L, Jones JA, Andritsos LA, Flynn JM, Heerema NA, Yang X, Rozewski D, Phelps M, Johnson, AJ, Grever MR, Byrd, JC."Activity of Combined Flavopiridol and Lenalidomide in Patients with Cytogenetically High Risk Chronic Lymphocytic Leukemia (CLL): Updated Results of a Phase I Trial" .
June 2011 Byrd JC, Blum KA, Burger JA, Coutre SE, Sharman JP, Furman RR, Flinn IW, Grant BW, Richards DA, Zhao W, Heerema NA,  Johnson AJ, Izumi R, Hamdy A, O'Brien SM."Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study" .

Inventions and Patents

Compositions and Methods for Increasing Drug Efficacy in Cancer

Autophagosome-Lysosome Fusion Inhibition Enhances Flavopiridol Efficacy in Cancer

Identification of endoplasmic reticulum stress-inducing agents by antagonizing autophagy: a new potential strategy for identification of anti-cancer therapeutics in B-cell malignancies.

TCL-1 Transgenic Mouse as a Model for Chronic Lymphocytic Leukemia

 

Presentations

Clinical rebirth of flavopiridol in chronic lymphocytic leukemia (CLL): Utilizing in vitro and in vivo pharmacodynamic measurements to improve efficacy and interrogate relevant mechanisms of action

The cyclin dependent kinase inhibitor SCH 727965 demonstrates dramatic pre-clinical activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia

Dinaciclib (SCH727965) Is a Novel Cyclin Dependent Kinase Inhibitor That Promotes Selective Apoptosis In CLL Cells and Abrogates the Protective Effects of Microenvironment Cytokines

The role of CDK and PI3 Kinase inhibitors in CLL

CAL-101, a selective inhibitor of the p110 delta isoform of phosphatidylinositol 3-kinase, effectively induces apoptosis in chronic lymphocytic leukemia cells providing a novel therapeutic strategy

Targeting the B-cell receptor in Chronic Lymphocytic Leukemia

Novel signaling inhibitors of CDK and PI3K

Novel therapies for CLL

Mechanisms of resistance of kinase inhibitors and how to prevent this

Targeting the B-cell receptor in chronic Lymphocytic Leukemia

Mechanisms of resistance of kinase inhibitors in CLL

When the clinic meets the laboratory - correlative studies and how to collaborate with scientists

Targeting the B-cell receptor in chronic lymphocytic leukemia

Mechanisms of action and resistance of CLL novel agents

Using the TCL1 mouse model for preclinical drug development in Chronic Lymphocytic Leukemia

Targeting the B-cell receptor in chronic lymphocytic leukemia

The overall high response rates in patients with chronic lymphocytic leukemia (CLL) to a new novel bruton tyrosine kinase (BTK) inhibitor called acalabrutinib (ACP-196)

Current Research on CLL

P13-Kinase Inhibitor Resistance

BTK as a therapeutic target: What is next?

 

Professional Activities

present Session Chair. XVI International Workshop on Chronic Lymphocytic Leukaemia.
present Review of Grant Application. Leukemia, Lymphoma Society 2015 Translational Research Program Grant Review. New York, NY.
present Review of Grant Application. Leukemia, Lymphoma Society 2016 Translational Research Program Grant Review. New York, NY.
present Session Moderator for an oral session. The American Society of Hematology Annual Meeting. San Diego, CA.
present Review of Grant Application. Italian Association for Cancer Research (AIRC).
2003 - present Leukemia and Lymphoma Society advocate.
2010 - present Pelotonia.
2016 - present Review of Grant Application. American Cancer Society, Leukemia, Immunology and Blood Cell Development.
2004 - 2010 Newsletter Editor. Columbus Roadrunner Club.
2006 - 2010 American Cancer Society Volunteer Ambassador. American Cancer Society.
2011 Review of Grant Applications. French National Cancer Institute.
2012 Review of Grant Applications. Paracelsus Private Medical University of Salzburg.
2013 Review of Grant Applications. Cancer Research UK.
2013 Review of Grant Applications. Austrian Science Fund.